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We present a previously undocumented complication of dystrophic calcification of the prostate after cryotherapy. An 87-year-old
male presented with recurrent lower urinary tract infections and was found to have an obstructing large calcified mass in the
right lobe of the prostate. Subsequently, he underwent transurethral resection of the prostate (TURP) and bladder neck with laser
lithotripsy to remove the calculus. We propose that chronic inflammation and necrosis of the prostate from cryotherapy resulted
in dystrophic calcification of the prostate. As the use of cryotherapy for the treatment of localized prostate cancer continues to
increase, it is important that clinicians be aware of this scenario and the technical challenges it poses.
1. Introduction
Dystrophic calcification occurs as a result of chronic inflam-
mation or tissue necrosis. It is associated with several medical
conditions such as collagen vascular disease, scleroderma,
and systemic lupus erythematosis as well as with soft tissue
injuries from trauma [1, 2]. In the genitourinary tract, dys-
trophic calcification has been reported in upper tract tumors,
renal parenchymal disease, and squamous cell carcinoma of
the bladder from schistosomiasis [3–5]. Cryotherapy of the
prostate is a minimally invasive technique to treat localized
prostate cancer. Under transrectal ultrasound (TRUS) guid-
ance, transperineal probes are inserted into the prostate and
cooled to −40∘C resulting in tissue injury and coagulative
necrosis. The most common side effects of cryotherapy are
transient urinary retention from swelling, erectile dysfunc-
tion, and urethral sloughing [6]. However, there have been
no reported cases of dystrophic calcification of the prostate
in relation to cryotherapy.
2. Case Presentation
An 87-year-old male presented with recurrent episodes of
hematuria and pelvic discomfort for six months due to recur-
rent lower urinary tract infections. He had a urological past
medical history significant for low risk Gleason 3 + 3 prostate
cancer (1/12 cores positive of right prostatic lobe only) treated
with primary right-sided prostatic focal cryotherapy in 1996.
His prostate cancer had been detected as a result of an
elevated PSA and an abnormal digital rectal examination. At
time of cryotherapy, he had no prostatic calcifications visible
on TRUS or CT scan. Since his treatment, his serum PSA
levels had been undetectable, and two subsequent CT scans of
the abdomen and pelvis were negative for lymphadenopathy
or evidence of metastatic disease. In addition, he had previ-
ously undergone a subtotal parathyroidectomy for hypercal-
cemia that had hence resolved before his diagnosis of prostate
cancer.
Physical examination of the patient revealed an alert
and oriented male with minimal suprapubic tenderness. On
digital rectal examination, the prostate was approximately
40 grams and smooth without irregularity. He had a 500 cc
postvoid residual. The remainder of physical examination
was within normal limits. Urine analysis was positive for
leukocyte esterase and 26WBC per HPF. His serum PSA was
undetectable. A noncontrast CT of the abdomen and pelvis
revealed bilateral renal cysts without hydronephrosis and a
17 × 15 × 12mm calcification of the right lobe of the prostate
(Figure 1).
The decision was made to proceed with TURP to relieve
the obstruction as his symptoms had not improved with oral
tamsulosin and finasteride. General anesthesia was induced,
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Figure 1: Axial image from the noncontrast pelvic CT scan demon-
strating the right prostatic calcificationmeasuring 17× 12mm in this
section.
and a 22F cystoscope was passed through the urethra into
the bladder without obvious signs of obstruction or trauma.
Upon further investigation, there was enlargement of the
right lateral lobe of the prostate from a protruding and visible
calcified growth at the right bladder neck consistent with
the previous CT findings. Lithotripsy with a holmium laser
failed to penetrate the embedded stone given the intermixed
soft tissue; therefore, a 27F resectoscope using a wedge loop
was utilized to remove prostate and bladder neck tissue
from around the stone. Once the soft tissue was removed,
another attempt to laser the stone was performed; however,
the laser failed to penetrate the stone. Again, the resectoscope
using a wedge loop was utilized and relatively large sheets
of stone were successfully removed with ease. A 24F three-
way urinary catheter was left in place to gentle traction with
continuous bladder irrigation overnight. The urine was clear
of continuous bladder irrigation on postoperative day one,
and the urinary catheter was removed. He was able to void
freely with minimal postvoid residual and was discharged
home that afternoon. Stone composition revealed calcium
phosphate (hydroxy and carbonic apatite).
3. Discussion
Dystrophic calcification occurs in areas of chronic inflam-
mation, tissue injury, and necrosis.This pathologic condition
is best understood in relation to atherosclerosis and forma-
tion of atheromatous plaques in the aorta and other large
arteries but is also well described in the rheumatologic and
dermatologic literature [7, 8]. The pathogenesis involves an
inciting event (nucleation) characterized by acute inflam-
mation, followed by propagation and deposition of calcium
phosphate crystals as chronic inflammation resolves. Tissue
injury leads to calcification in twoways: leakage of calcium by
damaged cell membranes becomes saturated to the point of
crystallization and the acidic microenvironment from tissue
necrosis inactivates endogenous calcification inhibitors [2, 9].
This process occurs in the corpora amylacea. Dystrophic cal-
cification is independent of calcium and phosphate; however,
high serum levels of these ions portend an increased risk of
soft tissue calcifications [10]. Benign prostatic calcifications
occur by a similar mechanism but on a much smaller level as
most calcifications are<3mm in greatest diameter and do not
coalesce into large, symptomatic stones [11, 12].
In contrast to dystrophic calcification that occurs in
injured tissue, metastatic calcifications occur in previously
normal tissue. Metastatic calcifications are classified as either
malignant or nonmalignant. As its name suggests, malignant
metastatic calcifications occur as a result systemic or local
malignancy—most notably parathyroid cancer, breast cancer,
multiple myeloma, lymphoma, and leukemia [13, 14]. While
the exact mechanism is not clearly understood, it is hypothe-
sized that metastatic calcification deposits occur as a result
of increased calcium metabolism from bone, induced by
parathyroid hormone related protein (PTHrP) or alternations
in expression of receptor activator of nuclear factor 𝜅-𝛽
(RANK) and RANK ligand [15]. The elevated serum of levels
of calcium ions can then precipitate in tissues that have
a transient local-regional alkaline pH. It is impossible to
predict wheremalignant metastatic calcifications will present
and in which specific patients; however, calcifications are
typically identified in the septa of the lungs, myocardium of
the heart, muscular layer and gastric mucosa of the stomach,
and the tubules of the kidneys [16]. Nonmalignant metastatic
calcifications occur in a similar pattern of distribution but are
attributed to benign causes such as hyperparathyroidism.
In the urology literature, benign prostatic calcifications
have been described as a consequence of intermittent bouts
of inflammation from recurrent urinary tract infections
and prostatitis [17]. Additionally, inflammation from laser
vaporization of the prostate for benign prostatic hyperplasia
(BPH) is associated with symptomatic superficial bladder
neck calcifications [18]. The mechanisms are likely similar
given that inflammation is the commonality. In both of these
reports, the calcifications typically presented as multiple,
small, less than 2-3mm calcifications, vastly different from
the 1.7 cm calcification seen in our patient’s prostate. Our
patient had a remote history of hyperparathyroidism treated
with subtotal parathyroidectomy years before he was diag-
nosed with prostate cancer. Since the time of treatment, his
serum calcium levels had been normal, and there were no
documented prostatic calcifications before his cryotherapy,
ruling out nonmalignant calcification as the cause of his
prostatic calcification.Additionally, from the time of the diag-
nosis of prostate cancer until present, there was no evidence
to suggest that the patient had any forms of solid organ or
systemic malignancy based upon laboratory findings, clinical
imaging, and physical exam. Dystrophic calcification of the
prostate is the most likely etiology of the patient’s prostate
stone as (1) the right prostatic calcification occurred in the
area of previous tissue injury and necrosis consistent with
the location of right-sided prostatic focal cryotherapy the
pathogenesis of dystrophic calcification, (2) there was no
evidence of calcification of any area of the prostate before
cryotherapy, and (3) there is no evidence to support any type
of metastatic calcification as the cause.
Early reports of surgical cryotherapy date back to the
late 1800s when cervical and breast masses were treated with
mixtures of salt and ice to reduce tumor volume and treat
local symptoms [19]. In the years to come, the technology
improved. In 1961, the first liquid nitrogen cryotherapy probe
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system was developed by Cooper and Lee, which allowed for
targeted freezing of tissue to −200 degrees Celsius [20]. The
technology was adopted by urologists Soanes and Flocks to
treat prostate cancer and BPHwith transperineal cryotherapy
through visual observation of tissue freezing; however, given
inadequate monitoring capabilities, many patients became
incontinent or developed fistulas [21, 22]. The advent of a
urethral warming catheter in the 1990s helped to prevent
these devastating complications but other surgicalmodalities,
such as open and robotic-assisted radical prostatectomy,
brachytherapy, and radiation for the treatment of prostate
cancer prevailed [23]. Now, in the 21st century, with more
emphasis on minimally invasive techniques and the develop-
ment of real-time ultrasound-guided imaging, cryotherapy of
the prostate has made resurgence as an acceptable alternative
in the management of localized prostate cancer.
Primary cryotherapy for the treatment of prostate cancer
is an option for men with T1-2 N0M0 localized disease
who have not previously undergone TURP [24]. Ideal can-
didates should not have large prostates, as this inhibits the
ability to uniformly achieve cold temperatures throughout
the entire gland. Liquid nitrogen has been replaced with
argon as the cooling medium. Percutaneous perineal probe
placement is performed under TRUS guidance; unilateral or
bilateral prostate templates can be utilized [25]. The five-year
biochemical disease-free survival rates are 65–92%, 69–89%,
and 48–89% for low-, intermediate-, and high-risk cases of
prostate cancer [26]. Additionally, salvage cryotherapy is a
treatment option for patients who fail prostate external beam
radiation therapy with recurrent focal disease.
Repeat imaging is not part of the standard follow-up care
after cryotherapy of the prostate and is only performed if a
patient has a persistently elevated prostate specific antigen
or abnormality on digit rectal examination. Therefore, it
is not known what percentage of patients develop sizeable
calcifications of the prostate after cryotherapy. In this patient,
the calcification protruded through the prostate and into
the bladder neck causing bladder outlet obstruction and
recurrent urinary tract infections. This suggests that the
cellular damage caused by the cryotherapy probe extended
well into the bladder neck to cause coagulation necrosis and
later dystrophic calcification.As the use of cryotherapy for the
treatment of localized prostate cancer continues to increase,
it is important that clinicians are aware of this potential
scenario and the technical challenges it poses.
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“Calcinosis cutis universalis in a patient with systemic lupus
erythematosus,”Clinical Rheumatology, vol. 25, no. 1, pp. 70–74,
2006.
[2] J. S. Walsh and J. A. Fairley, “Calcifying disorders of the skin,”
Journal of the American Academy of Dermatology, vol. 33, no. 5,
pp. 693–706, 1995.
[3] S. A. Merchant and P. P. Amonkar, “Genitourinary Bilharziasis:
a review,” Indian Journal of Radiology and Imaging, vol. 12, no.
2, pp. 239–244, 2002.
[4] R. B. Dyer, M. Y. M. Chen, and R. J. Zagoria, “Abnormal
calcifications in the urinary tract,” Radiographics, vol. 18, no. 6,
pp. 1405–1424, 1998.
[5] A. Tsujimura, T. Imazu, K. Nishimura et al., “Ureteropelvic
junction obstruction with renal pelvic calcification: a case
report,” The Journal of Urology, vol. 150, no. 6, pp. 1889–1890,
1993.
[6] D. Porres, D. Pfister, and A. Heidenreich, “Minimally invasive
treatment for localized prostate cancer,” Minerva Urologica e
Nefrologica, vol. 64, no. 4, pp. 245–253, 2012.
[7] R. M.Weiss, J. D. Miller, and D. D. Heistad, “Fibrocalcific aortic
valve disease: opportunity to understand disease mechanisms
using mouse models,” Circulation Research, vol. 113, no. 2, pp.
209–222, 2013.
[8] E. R.Mohler III, F. Gannon, C. Reynolds, R. Zimmerman,M.G.
Keane, and F. S. Kaplan, “Bone formation and inflammation in
cardiac valves,” Circulation, vol. 103, no. 11, pp. 1522–1528, 2001.
[9] C. M. Giachelli, “Ectopic calcification: gathering hard facts
about soft tissue mineralization,” The American Journal of
Pathology, vol. 154, no. 3, pp. 671–675, 1999.
[10] E. T. W. Demetriou, S. M. Pietras, and M. F. Holick, “Hyper-
calcemia and soft tissue calcification owing to sarcoidosis:
the sunlight-cola connection,” Journal of Bone and Mineral
Research, vol. 25, no. 7, pp. 1695–1699, 2010.
[11] K. S. Sfanos, B. A. Wilson, A. M. de Marzo, and W. B. Isaacs,
“Acute inflammatory proteins constitute the organic matrix of
prostatic corpora amylacea and calculi in men with prostate
cancer,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 106, no. 9, pp. 3443–3448, 2009.
[12] V. Smith, “Prostatic corpora amylacea and their calcification,”
Surgical Forum, vol. 16, pp. 501–502, 1965.
[13] R.M.Mulligan, “Metastatic calcification,”Archives of Pathology,
vol. 43, no. 2, pp. 177–230, 1947.
[14] E. D. Chan, D. V. Morales, C. H. Welsh, M. T. McDermott,
and M. I. Schwarz, “Calcium deposition with or without bone
formation in the lung,”TheAmerican Journal of Respiratory and
Critical Care Medicine, vol. 165, no. 12, pp. 1654–1669, 2002.
[15] M. Senba and K. Kawai, “Hypercalcemia and production of
parathyroid hormone-like protein in adult T-cell leukemia-
lymphoma,” European Journal of Haematology, vol. 48, no. 5, pp.
278–279, 1992.
[16] M. Senba and K. Kawai, “Metastatic calcification due to
hypercalcemia in adult T-cell leukemia-lymphoma (ATLL),”
Zentralblatt fur Pathologie, vol. 137, no. 4, pp. 341–345, 1991.
[17] C. G. Hong, B. I. Yoon, H.-S. Choe, U.-S. Ha, D. W. Sohn,
and Y.-H. Cho, “The prevalence and characteristic differences
in prostatic calcification between health promotion center and
urology department outpatients,” Korean Journal of Urology,
vol. 53, no. 5, pp. 330–334, 2012.
[18] S.-W. Jeon, Y.-K. Park, and S.-G. Chang, “Dystrophic calcifi-
cation and stone formation on the entire bladder neck after
Potassium-titanyl phosphate laser vaporization for the prostate:
a case report,” Journal of Korean Medical Science, vol. 24, no. 4,
pp. 741–743, 2009.
4 Case Reports in Urology
[19] A. A. Gage, “A history of cryosurgery,” Seminars in Surgical
Oncology, vol. 14, no. 2, pp. 99–109, 1998.
[20] I. S. Cooper and A. S. Lee, “Cryostatic congelation: a system for
producing a limited, controlled region of cooling or freezing of
biologic tissues,”The Journal of Nervous andMental Disease, vol.
133, pp. 259–263, 1961.
[21] W. A. Soanes, M. J. Gonder, and S. Shulman, “Apparatus and
technique for cryosurgery of the prostate.,” Journal of Urology,
vol. 96, no. 4, pp. 508–511, 1966.
[22] R. H. Flocks, C. M. Nelson, and D. L. Boatman, “Perineal
cryosurgery for prostatic carcinoma,” The Journal of Urology,
vol. 108, no. 6, pp. 933–935, 1972.
[23] J. K. Cohen, R. J. Miller, and B. A. Shuman, “Urethral warming
catheter for use during cryoablation of the prostate,” Urology,
vol. 45, no. 5, pp. 861–864, 1995.
[24] A. Zisman, A. J. Pantuck, J. K. Cohen, and A. S. Belldegrun,
“Prostate cryoablation using direct transperineal placement of
ultrathin probes through a 17-gauge brachytherapy template-
technique and preliminary results,” Urology, vol. 58, no. 6, pp.
988–993, 2001.
[25] T. J. Polascik, I. Nosnik, J. M. Mayes, and V. Mouraviev,
“Short-term cancer control after primary cryosurgical ablation
for clinically localized prostate cancer using third-generation
cryotechnology,” Urology, vol. 70, no. 1, pp. 117–121, 2007.
[26] D. K. Bahn, F. Lee, R. Badalament, A. Kumar, J. Greski, and
M. Chernick, “Targeted cryoablation of the prostate: 7-Year
outcomes in the primary treatment of prostate cancer,”Urology,
vol. 60, no. 2, pp. 3–11, 2002.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
